All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Real-world efficacy of Isa-Kd in patients with RRMM
|
The Isa-Kd regimen is approved by the U.S. FDA and the EMA for the treatment of patients with RRMM.1 This approval is based on results from the phase III IKEMA trial (NCT03275285), which were previously reported by the Multiple Myeloma Hub.1 However, data on the real-world efficacy of Isa-Kd are limited.1 An Italian, multicenter, retrospective analysis evaluated the safety and efficacy of Isa-Kd in a real-world population of 103 patients with RRMM.1 Results from this analysis were published in the European Journal of Haematology by De Novellis, et al.1 |
| Key learnings |
| The best ORR was 87%, with sCR/CR, VGPR, and PR rates of 18%, 39%, and 27%, respectively, and with a median time to best response of 3 months and a median number of cycles of 6. |
| The median PFS and OS were not reached, and the 1-year PFS and OS rates were 72% and 77%, respectively. |
| The safety findings were consistent with the safety profile of Isa-Kd in the IKEMA trial, with manageable rates of hematological (42%) and cardiac (24%) toxicities. |
| In a subgroup analysis of patients who received 1 prior line of therapy (n = 69), the best ORR, sCR/CR, VGPR, and PR rates were 88%, 20%, 46%, and 22%, respectively. Median PFS and OS were not reached, and the 1-year PFS and OS rates were 92% and 95%, respectively. |
| These results confirm the effectiveness of Isa-Kd in real-world patients with RRMM. The promising efficacy of Isa-Kd in patients with 1 prior line of therapy may influence therapeutic algorithms by encouraging Isa-Kd earlier in the treatment sequence for fit patients. |
Abbreviations: CR, complete response; EMA, European Medicines Agency; FDA, Food and Drug Administration; Isa-Kd, isatuximab, carfilzomib, and dexamethasone; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; RRMM, relapsed/refractory multiple myeloma; sCR, stringent CR; VGPR, very good PR.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?
